Antihypertensive panel: Looking beyond conventional methods
LC-MS/MS testing provides clear results for patients
Resistant hypertension, defined as blood pressure remaining above goal despite treatment with three or more antihypertensive medications, is often driven by prescription nonadherence rather than true treatment resistance. Our antihypertensive panel identifies if a patient has taken their prescribed medication within the past 24 hours. This panel allows healthcare professionals to objectively address noncompliance or consider alternative treatments if there are tolerance issues. The targeted information provided by this panel can prevent overprescribing and related complications.
Key testing
- AHPRU | Antihypertension Panel, Random, Urine
- Assesses whether a patient has taken a prescribed medication in the previous 24 hours.
- Provides a more direct method to assess whether a patient is taking a certain medication to aid in patient management.
- Detects five commonly available diuretics.
- Assists physicians in avoiding overprescription of additional medications and medication complications.
- Helps prevent costly and time-consuming directly observed therapy.
Frequently asked questions
What are the included medications?
- Amlodipine
- Atenolol
- Bumetanide
- Carvedilol
- Chlorthalidone
- Clonidine
- Furosemide
- Hydralazine
- Hydrochlorothiazide
- Labetalol
- Lisinopril
- Losartan
- Metoprolol
- Spironolactone
- Test measures metabolite
- Terazosin
- Torsemide
Can a value be provided for the medication?
Measured urine concentrations can be influenced by multiple factors, including urine dilution and the timing of medication administration relative to specimen collection. As a result, interpreting the exact quantitative values is less meaningful than determining the presence or absence of the medication.
Accordingly, this test is intended solely to inform the provider whether a medication or its metabolite can be reliably detected in urine. It is not designed to assess the dose taken or administered, as dose interpretation would require a highly controlled specimen collection protocol and detailed clinical context.
What are the specimen requirements?
- Type: Urine (no preservative)
- Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
- Container/Tube: Plastic, 5-mL tube
- Specimen Volume: 4 mL (1mL minimum)
What are the best practices for when to order testing from Mayo providers? How are other providers utilizing testing? How is Mayo Clinic using the AHPRU test? What is the testing protocol?
This is a new test and, as such, is not fully embedded in any clinical protocols at this time. Based on the literature, we recommend using this test in patients with resistant hypertension on three or more prescribed medications. If one or more of those medications is not detected in the urine sample, a provider can have a targeted, open discussion with the patient regarding those specific medications. The hope is to find out whether the patient has a specific reason for not taking medications (e.g., negative side effects, lifestyle issues with the dosing regimen, or cost considerations), any of which they may have hesitated to bring up with a provider.
Is this test covered by insurance?
The urine antihypertensive panel is billed under HCPCS code G0481. Due to concerns about fraud, waste, and abuse, urine toxicology testing is closely monitored by payers. While this testing is not used for addiction treatment, use of code G0481 may trigger review under commercial or Medicare policies. Clients should consult with their revenue cycle or payer relations teams to understand reimbursement specifics.
Why isn’t it possible to determine a time range for when a patient may have stopped taking their medication?
There are several reasons why we are not able to determine precisely when a patient may have taken their medication:
- Pharmacogenetics: A patient's unique genetic makeup can affect how quickly they metabolize a drug (fast metabolizers or slow metabolizers).
- Kidney function: Impaired renal function (common in hypertensive patients) will lengthen the half-life and extend the time the drug can be detected.
- Hydration: Extreme dehydration can temporarily concentrate metabolites, extending the detection window.
- Pharmacokinetics: Due to the wide variance in half-lives across different antihypertensive medication classes, the time window for detecting a drug in urine — and therefore the time period that confirms recent adherence — is unique for every medication on the AHPRU panel.
What are the reference ranges for each of the drugs included in the panel?
The reference values are different for each of the drugs included in the panel:
- Amlodipine: 400 ng/mL
- Atenolol: 800 ng/mL
- Bumetanide: 40 ng/mL
- Carvedilol: 40 ng/mL
- Chlorthalidone: 4 ng/mL
- Clonidine: 40 ng/mL
- Furosemide: 4 ng/mL
- Hydralazine: 400 ng/mL
- Hydrochlorothiazide: 10 ng/mL
- Labetalol: 40 ng/mL
- Lisinopril: 1,000 ng/mL
- Losartan: 4 ng/mL
- Metoprolol: 40 ng/mL
- 7-alpha-Thiomethylspironolactone: 10 ng/mL
- Terazosin: 4 ng/mL
- Torsemide: 40 ng/mL
These reference ranges reflect the cutoff between detected versus nondetected that we have determined based upon a combination of our ability to accurately measure the drug or its metabolite and the correlation with the clinical validation in patients known to have dosed or not dosed with that medication.
Can additional medications (e.g., valsartan, irbesartan, olmesartan, telmisartan, nifedipine) be added to this testing?
We are looking to add more antihypertensive medications to this test in the future, but currently do not have a timeline for any new additions.
How long is the detection window? Can it go beyond 24 hours?
During validation of this test, samples were taken from patients who were known to have been dosed or not dosed with the medications on the panel on the day prior to specimen collection. We were able to detect all medications that had been dosed in the validation samples. The test may be able to detect medications taken more than one day prior; however, additional, longer durations were not validated.
How do you deal with a patient who says they forgot to take their medications the day before?
We recommend addressing the issue openly and honestly with the patient to explore potential reasons for missed doses and to identify any interventions that may help improve adherence. Follow-up can then be guided by the outcome of that discussion.
What do I tell my patients about why I am doing this testing?
Each physician may have their own approach to discussing this testing with their patients. One suggestion would be that this test can determine whether a patient's medications are being absorbed into the blood system, where they can then be eliminated by the kidneys. There can be many reasons why we do not detect any patient medications by the tests, and once we see the results, we can focus on those medications that are not detected to see if we can figure out why.
Will we detect any other drug metabolites or just parent drugs during the testing?
This assay only looks for the parent drugs for all the medications included, except for spironolactone, which tests only for the metabolite.
Are there any guidelines associated with this testing?
The 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines recommends that adults with uncontrolled hypertension placed on new or intensified medical therapy should have follow-up evaluations for medication adherence and response to treatment at monthly intervals until control is achieved. Further, chemical adherence testing of antihypertensive drug levels is one method to assess adherence.
How often should a patient be tested?
Testing frequency must be determined on a case-by-case basis. The test is most useful in a patient with resistant hypertension who is taking three or more medications.
What is the turnaround time for the test?
This test has a turnaround time of 2–9 days and is run only on Fridays.
Explore the advantages of Mayo Clinic Laboratories’ ANTIHYPERTENSIVE PANEL.
Learn more about our complete menu of renal testing. Schedule a time to discuss with one of our clinical specialists.